Human T lymphotropic virus type I (HTLV-I) is an exogenous RNA tumor virus etiologically linked to adult T cell leukemia and related diseases. In this paper, we describe that two 2',3'-dideoxynucleoside analogues, erythro 3'-azido-2',3'-dideoxythymidine (also called azidothymidine) and 2',3'-dideoxycytidine can inhibit the infectivity of HTLV-I against helper/inducer T cells in vitro.
Introduction
Human T lymphotropic virus type I (HTLV-I)' is an exogenous RNA tumor virus associated with adult T cell leukemia (ATL) (1) (2) (3) (4) (5) , a fulminant malignancy endemic in several parts of the world (6, 7) , which includes southwestern parts of Japan. In the United States, HTLV-I infection (alone or in combination with other pathogenic retroviruses) appears to be a growing problem, (3, 4) . ATL was first reported as a clinical entity in Japan (9-1 1). It has recently been recognized that HTLV-I can cause a wide spectrum ofdiseases, including an immunodeficiency state not necessarily accompanied by leukemia (12) . Atypical cases of ATL (13) , asymptomatic carriers (14), and neurological abnormalities such as HTLV-I-associated myelopathy (15) have been reported. Also, HTLV-I infection might be associated with tropical spastic paraparesis (16) . Although the mechanisms of natural transmission of HTLV-I are not fully understood, seroepidemiological studies suggest horizontal and/or vertical transmission ofHTLV-I (4, 6, 7). Moreover, cases oftransfusionassociated HTLV-I infections are not uncommon in certain endemic areas (17) . These observations have prompted us to attempt to explore strategies for preventing the replication and transmission of HTLV-I (18) .
All retroviruses, including HTLV-I, require a viral DNA polymerase called reverse transcriptase (RT) in their natural cycle of replication (19, 20) . Mitsuya et al. (21) (22) (23) have recently reported that 2',3'-dideoxynucleoside analogues can inhibit the infectivity and cytopathic effect of another human retrovirus, human T lymphotropic virus type III (HTLV-III) (also called lymphadenopathy-associated virus [LAV] or acquired immunodeficiency syndrome (AIDS)-related virus; recently, the human retrovirus subcommittee of the International Committee on the Taxonomy ofViruses has proposed that AIDS retroviruses by officially designated as human immunodeficiency virus, HIV [24] ), which is considered to be the causative agent of AIDS. These in vitro experiments have been done using a dose ofvirus greatly in excess ofthe minimal cytolytic dose (21, 22) . However, the extrapolation from HTLV-III (a virus that can readily infect target cells by cell-free virions and that has as its hallmark the capacity to destroy helper/inducer T cells) to HTLV-I (a virus that in general requires cell-associated virion transmission for infection and that has as its hallmark the capacity to transform helper/inducer T cells) is not straightforward. In the present study, we investigated the effect of two dideoxynucleoside analogues, erythro 3'-azido-2',3'-dideoxythymidine (also called azidothymidine [AZT] ) and 2',3'-dideoxycytidine (ddCyd) on the infectivity of HTLV-I by using cloned, normal helper/inducer T cells as target cells. We now report the capacity of AZT and ddCyd to inhibit the infectivity and replication of HTLV-I in vitro.
Methods
Target cells. We have previously described the method for generating normal tetanus-toxoid-specific helper T cell clones (25) , and one such normal OKT4' clone (TM-1 1) was used as a target cell line for this 394 study. Briefly, TM-I l was generated from a normal individual whose serum was negative for anti-HTLV-I antibody. TM-Il cells were maintained in 15% (vol/vol) interleukin 2 (IL-2, lectin depleted; Cellular Products, Buffalo, NY)-containing complete medium (RPMI 1640 supplemented with 4 mM L-glutamine; 50 MAM 2-mercaptoethanol; 15% undialyzed, heat-inactivated fetal calf serum; and antibiotics). TM-Il cells undergo a proliferative reaction in response to tetanus-toxoid in the presence of irradiated (4,000 rad), autologous peripheral blood mononuclear cells (PBM). This clone displays the following surface phenotypes: T3+, T4+, T8-, HLA-DR+, and Tac-antigen+.
Nucleosides. AZT was kindly provided by Wellcome Research Laboratory, whereas ddCyd was purchased from Calbiochem-Behring Corp., La Jolla, CA.
Cell culture. Target TM-I1 cells were stimulated with antigen plus irradiated, autologous PBM 6 d before the experiment. Growing TM-11 cells (5 X 106) were co-cultured with 106 lethally irradiated (12,000 rad), HTLV-I-producing M.J.-tumor cells (26) in 24-well culture plates (Costar, Cambridge, MA) in 2 ml of 15% IL-2-containing complete medium in the presence or absence of various concentrations of the compounds. Cells were continuously exposed to IL-2 and cultured at 370C in humidified air containing 5% CO2.
On day 2 of culture, one half of the medium was replaced with fresh medium containing the same concentrations of the compounds. After On day 9 of culture, higher concentrations of the compounds were reduced: AZT, from 9 and 27MAM to 4.5 and 10M ;M, respectively, whereas ddCyd, from 8 WM to 4 MM. Other concentrations were maintained throughout the study. On day 18 when the control virus-unexposed, drug-unexposed cells reached a plateau and stopped replicating, all the cultured populations were analyzed for the expression ofviral gag proteins (p24 and p19) by an indirect immunofluorescence assay and for the amount of HTLV-I proviral DNA in cellular DNA by Southern blot hybridization (see below). Aliquots of the cells were sometimes frozen, stored in liquid nitrogens, and subsequently thawed.
Detection ofHTLV-I gag protein expression. Methanol-acetone-fixed cells were analyzed by an indrect immunofluorescence assay for the presence of HTLV-I gag proteins using murine monoclonal antibody specifically against HTLV-I gag protein p19 and goat anti-serum against HTLV-I gag protein p24 (kind gifts from Dr. M. Robert-Guroff, National Cancer Institute, Bethesda, MD) according to published methods (27, 28) .
Southern blot hybridization. Southern blot hybridization was performed as previously described (2) . Briefly, high molecular weight DNA was extracted with organic solvents. 40 Mg (unless otherwise stated) of DNA were digested for 16 h at 37°C with 60 U of the restriction endonuclease Bam HI (Bethesda Research Laboratories, Gaithersburg, MD). The digests were subjected to electrophoresis overnight at 40 V in 0.8% agarose, transferred to nitrocellulose, and hybridized with a "P-nick translated HTLV-I probe (lambda MT-2), which detects the whole sequence of HTLV-I (29) . Proviral digestion fragments were detected by autoradiography with Kodak AR film using a screen (DuPont Quanta HII; DuPont Photo Products, Burbank, CA). Subsequently, the blots were 
Results
Growth characteristics of TM-li cells exposed to HTLV-I and cultured with AZTorddCyd. To (Fig. 1) . In contrast, TM-II cells exposed to HTLV-I and cultured without the dideoxynucleosides continued to proliferate, and this became particularly evident around day 18 . This observation suggests that at least some populations in TM-1I cells were infected and transformed by HTLV-I. When TM-1I cells were exposed to HTLV-I and cultured in the presence of AZT or ddCyd, the cells reached a plateau and stopped replicating, a pattern similar to that of the control virus-unexposed, drug-unexposed TM-11 cells (Fig. 1) . However, note that at higher concentrations of the drugs the growth of TM-I 1 cells appeared to be suppressed and some concentrations were reduced on day 9 and after being in culture (see Methods).
Inhibition of HTLV-I gag protein expression by AZT substantial differences in the number of TM-il cells, we harvested the cells and assessed them for the expression of HTLV-I gagproteins (Fig. 2) . TM-Il cells cultured alone were negative for the exptession ofgag proteins. When TM-Il cells were exposed to HTLV-I and cultured in the absence ofthe compounds, 16 and 13 cells per 1,000 TM-II cells were found to express viral gag proteins pi9 and p24, respectively. In the presence of 3 MM AZT or 0.5 MM ddCyd, a substantial decrease of the gag protein expression was observed. When the cells were exposed to HTLV-I and cultured at higher concentrations of the compounds, virtually no gag protein expression could be detected (Fig. 2) . Numbers of the gag protein-positive cells in the populations exposed to the virus in the absence ofdideoxynucleosides appeared not to be as high as could be expected from the differences in the growth curves of HTLV-I-exposed and -unexposed TM-il cell populations. As has been observed in other settings (4, 25, 32) , it would appear that there is some restriction of viral gag protein expression in these cells.
AZTandddCyd inhibit HTL V-I infection detected asproviral DNA. Since certain cells may not express the viral components even if they bear integrated HTLV-I proviruses (4, 25, 32), we examined proviral DNA in cellular DNA using Southern blot analysis. On day 18 ofculture, high molecular weight DNA was extracted from each cell population and was assessed for the presence of HTLV-I proviral DNA. DNA from each cell population was digested with Bam HI (which cuts three times within the HTLV-I-M.J. provirus, yielding a 4.0-kilobase (kb), gagpol-containing internal fragment, a 1-kb env-containing internal fiagment, and 3' and 5' junctional fiagments) and hybridized with a radiolabeled HTLV-I-specific probe. No proviral DNA was found in DNA from normal TM-I 1 cells that were cultured alone (Fig. 3, I -A, lane a). When cells were cultured with M.J.-tumor cells, polyclonally integrated HTLV-I proviruses were detected as a diffuse, indistinct smear of junctional fragments and a 4-kb internal fragment (Fig. 3, I-A, lane b) . However, in the presence of3 AM AZT, a substantial decrease ofthe amount of proviral DNA was observed in the Southern blot analysis (Fig. 3, I-A, lane c) . Densitometry readings of the exposed film showed an 87% decrease in the amount of proviral DNA at 3 AM AZT, with very little apparent toxicity to the cells due to AZT per se (Fig. 1) . At higher concentrations of AZT (9 and 27 AiM; after day 9, culture reduced to 4.5 and 9 MM), no proviral DNA was detected (Fig. 3, I-A, lanes d and e) . Densitometry readings of the exposed film confirmed a complete (100%) (Fig. 1) . The same blot was rehybridized with a radiolabeled TCR-f3 probe as a control indicator of the amounts of DNA used in the Southern blot experiments (Fig. 3, I We then assessed the anti-viral effect of ddCyd in the same system. As shown in Fig. 3 , II-A, lane c, when TM-l 1 cells were exposed to HTLV-I and cultured in the presence of 0.5 gM ddCyd, a moderate decrease ofthe amounts of HTLV-I provirus was observed, and densitometry reading of the film showed a 50% decrease in the amount of HTLV-I proviral DNA. At the same time, there was little or no drug-induced toxicity (Fig. 1) . In the presence of 2 and 8 !M ddCyd, no proviral DNA could be detected (Fig. 3, II-A, lanes d and e) , and densitometry confirmed a complete inhibition ofthe HTLV-I viral DNA synthesis. Consider that at these concentrations -40-60% decrease in numbers of viable TM-I 1 cells was noted on day 18 (Fig. 1) . When the DNA from MJ-tumor cells (a source of infectious virions) was hybridized with the HTLV-I probe, after Bam HI digestion, a multiple polyclonal integration ofHTLV-I proviruses was observed (Fig. 3, II-A, lane f) . This pattern is commonly seen in cultured HTLV-I-producing cells. The same blot was then rehybridized with the TCR-,B probe (Fig. 3, II-B) . Results indicate that the amounts ofcellular DNA loaded were essentially equal (except lane f in which half the amount of DNA was loaded). The presence of proviral DNA reflects actual infection by the virus; therefore, these data suggest that AZT and ddCyd blocked in vitro HTLV-I infection of normal helper/inducer T cells.
On day 22 of culture, each TM-I 1 cell population was extensively washed to remove the dideoxynucleosides and continuously cultured in the absence of the compounds. The cells exposed to HTLV-I and cultured without the compounds as well as the cells exposed to HTLV-I and cultured with 3 uM AZT or 0.5 1sM ddCyd could be maintained for 2 6 mo without further antigenic stimulation. However, TM-11 cells exposed to HTLV-I and cultured with 9 and 27 MM AZT or 2 and 8 MM ddCyd failed to continuously replicate on days 13-16 and then died out by day 40 of culture even in the presence of exogenous IL-2 as did the control HTLV-I-unexposed cells (data not shown).
Helper/inducer T cells protected by ddCyd remain immunologically competent. When helper/inducer as well as killer/ suppressor T cells are infected and transformed by HTLV-I, they often lose their dependence on IL-2, replicate spontaneously, and tend to lose their immunoreactivities (25, 32-35, Matsushita, S., H. Mitsuya, M. S. Reitz, J. B. Trepel, R. F. Jarrett, K. Takatsuki, and S. Broder, manuscript in preparation). We then asked if the T cells protected by dideoxynucleosides against the infectivity ofHTLV-I retained their dependence on IL-2 and normal immune reactivities. The TM-I 1 populations, which had been exposed to HTLV-I, cultured in the absence ofddCyd, and then harvested on day 20 of culture showed both spontaneous and tetanus-toxoid-induced replication in the presence of irradiated, autologous PBM as a source of accessory cells (Table I, Exp. 1). In contrast, TM-l 1 cells, which had been exposed to HTLV-I, but had been protected by ddCyd and had borne no detectable HTLV-I provirus as described above, proliferated only in response to tetanus-toxoid and did not show a spontaneous replication. The magnitude of the antigen-induced response of the TM-I 1 cells "protected" by ddCyd was largely comparable to that ofHTLV-I-unexposed and ddCyd-unexposed TM-11 populations. We continued the culture of TM-1 cells infected with HTLV-I (TM-I -H) for an additional 8 wk and asked if TMIl-H retained the capacity to respond to antigen for a prolonged period of time after HTLV-I infection (Table I, Exp. 2). Data indicate that TM-I 1-H exhibited only spontaneous replication (in the absence of IL-2) and showed no capacity to proliferate in response to antigen, as we and other investigators have reported in previous work (25, (32) (33) (34) (35) . These results suggest that helper/inducer T cells, exposed to HTLV-I that would result in infection, transformation, and loss of antigen-specific immune reactivity, but protected by ddCyd, retain the normal dependence on IL-2 and the capacity to respond to antigen in vitro.
Discussion
Because a rapid and efficient system for in vitro transmission of HTLV-I has not yet become available, it has been difficult to assess the effect of putative anti-viral drugs against HTLV-I. In this study, we attempted to establish a system to analyze the effect of possible anti-viral agents on the infectivity of HTLV-I in a relatively short time period by using an antigen-specific helper/inducer T cell clone as a target population. Since certain cells may not express the viral components even if they bear integrated HTLV-I proviruses (25, 32) , we examined total proviral DNA in a given amount ofcellular DNA by Southern blot hybridization. The data reported here suggest that two 2',3'-dideoxynucleoside analogues, AZT and ddCyd, have the potential to function as an anti-viral agent against the infectivity ofHTLV-I in vitro. Although at higher concentrations ofAZT and ddCyd, moderate to substantial cytotoxicity was observed, decreasing the dosage lessened the toxicity and the TM-11 cells could continuously grow with virtually the same growth pattern as the control virus-unexposed and drug-unexposed cells. We observed an almost complete inhibition ofproviral DNA synthesis in the target cells exposed to HTLV-I in the presence of 2 9 AM of AZT or .2 AM of ddCyd as assessed by Southern blot hybridization technique. At these concentrations both compounds also clearly blocked viral replication by using the expression of HTLV-I gag protein in the cells as an index of HTLV-I replication. Moreover, the compounds appeared to block the virusinduced transformation in the target helper/inducer T cells without affecting their immunoreactivities. These data suggest that there is a range of the drugs that can provide a protection against HTLV-I without unacceptable toxicity at least in vitro.
The capacity of2',3'-dideoxynucleosides to potentially inhibit HTLV-I replication and HTLV-I-mediated transformation is important from several points of view. Ongoing replication of human pathogenic retroviruses could be important in certain human diseases (21) (22) (23) 36 ). Moreover, the capacity of these drugs to inhibit HTLV-I-mediated transformation in vitro could conceivably shed light on how this virus acts as an oncogenic agent in vivo. The transformation event might be linked to HTLV-I infection per se. On the other hand, it is conceivable that a process ofchromosome-mediated transfer of(unregulated) genes after fusion events between donor and recipient cells brings about the transformed state. If the former mechanism is operative, transformation should be sensitive to chain-terminating nucleoside inhibitors of RT. Ifthe latter mechanism is operative, this would not be the case. Our data are compatible with the idea that HTLV-I infection, rather than chromosome-mediated transfer ofgenes alone, is responsible for the transforming properties of the virus.
It should be noted that AZT and ddCyd are not new chemicals, and pioneering studies on these compounds were initiated in the 1960s and 1970s, before human retroviruses were proven to exist (37) (38) (39) (40) (41) (42) . At least one mechanism by which such agents function is to compete with the normal nucleotide counterpart for incorporation into retroviral DNA. These agents must undergo anabolic phosphorylation by host cell kinases before they can mediate an anti-retroviral effect. When the 3'-hydroxyl group of the deoxynucleosides is substituted by hydrogen or other groups, it is not possible for the corresponding nucleotide to form the 5' --3' phosphodiester linkages necessary for DNA elongation in the replication of retrovirus. There are data that (i) AZT and ddCyd are converted to 5'-triphosphates by cellular enzymes (43, 44) , (ii) the triphosphate products are utilized by HTLV-III/LAV DNA polymerase (or RT) and inhibit DNA synthesis mediated by purified HTLV-III/LAV RT (45) , and (iii) cellular DNA polymerase alpha is rather resistant to these dideoxynucleosides as a triphosphate form (42). Furthermore, (iv) in previous work, the data suggest that at concentrations that are achievable in human cells, dideoxynucleoside-5'-triphosphates can serve as substrate for the HTLV-Ill RT to elongate a DNA chain by one residue, after which the chain is terminated (45) . Certain dideoxynucleosides can thus act as DNA chain-terminators in human retroviral DNA synthesis, although this need not be the only mechanism for their anti-retroviral activity.
2',3'-Dideoxynucleosides can potentially have an effect against virtually any retrovirus, provided that host target cells can supply the appropriate level of anabolic phosphorylation. Recently we have learned that 2',3'-dideoxynucleoside analogues can profoundly suppress the replication of animal lentiviruses such as caprine arthritis-encephalitis virus and equine infectious anemia virus, as well as the focus formation induced by a transforming muine type C retrovirus, Kirsten murine sarcoma virus, in a system that requires only a single-round viral DNA formation and integration (46) .
Seroepidemiological studies on HTLV-I have suggested that sexual transmission (originally from husband to wife) and mother-to-child transmission represent common modes of spreading of HTLV-I (4, 6, 7). Transfusion-associated transmission is another mode of viral transmission (17) . It is possible that AZT and ddCyd or other related agents could be used in certain clinical setings to block the infectivity of HTLV-I, and thereby to suppress the transmissibility of the virus. It is also possible that anti-viral drugs may have a role in prophylaxis or treatment of HTLV-I-associated diseases if ongoing replication of HTLV-I has clinical relevance as seen in certain patients who appear to be in remission or preleukemic stage (36). Taken together, our observations may be of value in developing a new pharmacological strategy for preventing the replication and blocking the transmission of HTLV-I and related pathogenic retroviruses in human beings (47) (48) (49) .
